Feurstein Simone, Rücker Frank G, Bullinger Lars, Hofmann Winfried, Manukjan Georgi, Göhring Gudrun, Lehmann Ulrich, Heuser Michael, Ganser Arnold, Döhner Konstanze, Schlegelberger Brigitte, Steinemann Doris
Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
BMC Genomics. 2014 Sep 11;15(1):784. doi: 10.1186/1471-2164-15-784.
Acute myeloid leukemia with complex karyotype (CK-AML) is a distinct biological entity associated with a very poor outcome. Since complex karyotypes frequently contain deletions of the chromosomal region 12p13 encompassing the tumor suppressor genes ETV6 and CDKN1B, we aimed to unravel their modes of inactivation in CK-AML.
To decipher deletions, mutations and methylation of ETV6 and CDKN1B, arrayCGH, SNP arrays, direct sequencing of all coding exons and pyrosequencing of the 5'UTR CpG islands of ETV6 and CDKN1B were performed. In total, 39 of 79 patients (49%) showed monoallelic deletions of 12p13 according to karyotypic data and 20 of 43 patients (47%) according to genomic profiling. Genomic profiling led to the minimal deleted region covering the 3'-UTR of ETV6 and CDKN1B. Direct sequencing revealed one novel monoallelic frameshift mutation in ETV6 while no mutations in CDKN1B were identified. Furthermore, methylation levels of ETV6 and CDKN1B did not indicate transcriptional silencing of any of these genes. ETV6 and CDKN1B had reduced expression levels in CK-AML patients with deletion in 12p13 as compared to CK-AML without deletion in 12p13, while the other genes (BCL2L14, LRP6, DUSP16 and GPRC5D) located within the minimal deleted region in 12p13 had very low or missing expression in CK-AML irrespective of their copy number status.
ETV6 and CDKN1B are mainly affected by small monoallelic deletions, whereas mutations and hypermethylation play a minor role in CK-AML. Reduced gene dosage led to reduced gene expression levels, pointing to haploinsufficiency as the relevant mechanism of inactivation of ETV6 and CDKN1B in CK-AML.
伴有复杂核型的急性髓系白血病(CK-AML)是一种生物学特性独特且预后极差的疾病实体。由于复杂核型常包含12p13染色体区域的缺失,该区域包含肿瘤抑制基因ETV6和CDKN1B,我们旨在阐明它们在CK-AML中的失活模式。
为了解析ETV6和CDKN1B的缺失、突变及甲基化情况,进行了比较基因组杂交芯片(arrayCGH)、单核苷酸多态性(SNP)芯片分析、所有编码外显子的直接测序以及ETV6和CDKN1B 5'非翻译区(UTR)CpG岛的焦磷酸测序。根据核型数据,79例患者中有39例(49%)显示12p13单等位基因缺失,根据基因组分析,43例患者中有20例(47%)显示该缺失。基因组分析确定了最小缺失区域,该区域覆盖ETV6和CDKN1B的3'-UTR。直接测序发现ETV6有一个新的单等位基因移码突变,而未在CDKN1B中鉴定到突变。此外,ETV6和CDKN1B的甲基化水平并未表明这些基因中的任何一个存在转录沉默。与12p13无缺失的CK-AML患者相比,12p13有缺失的CK-AML患者中ETV6和CDKN1B的表达水平降低,而位于12p13最小缺失区域内的其他基因(BCL2L14、LRP6、DUSP16和GPRC5D)在CK-AML中的表达极低或缺失,与它们的拷贝数状态无关。
ETV6和CDKN1B主要受小的单等位基因缺失影响,而突变和高甲基化在CK-AML中起次要作用。基因剂量减少导致基因表达水平降低,表明单倍体不足是CK-AML中ETV6和CDKN1B失活的相关机制。